Navigation Links
Particle Sciences Acquires Additional Space for Operations
Date:11/10/2009

BETHLEHEM, Pa., Nov. 10 /PRNewswire/ -- Particle Sciences Inc., a leading pharmaceutical CRO, has further expanded their capabilities by the acquisition of additional space bringing their total to approximately 21,000 sq ft. "Our current workload and existing pipeline simply necessitates this addition," says Dr. Mark Mitchnick, CEO. "2009 has been a record year for us and we have pretty good visibility on the next 12 months. The additional space will be used to expand our cGMP warehouse capacity. Also, we will construct a purpose-built sampling and weighing area for highly potent materials," says Mitchnick. According to Robert Lee, PhD, Particle Sciences VP of Pharmaceutical Development, "Increasingly, clients are coming to us for clinical trial material manufacturing and to work with a greater number of highly potent compounds. We are fortunate that we are able to expand into both of those needs." Particle Sciences expects the new space to be operational in Q1 2010.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit http://www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

    Contact:
    Maureen Cochran
    mcochran@particlesciences.com
    (610) 861-4701

SOURCE Particle Sciences, Inc.


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pitt-led researchers create nanoparticle coating to prevent freezing rain buildup
2. Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology
3. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
4. Engineers produce how-to guide for controlling the structure of nanoparticles
5. New discovery reveals fate of nanoparticles in human cells
6. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
7. Bio-enabled, surface-mediated approach produces nanoparticle composites
8. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
9. Capping a two-faced particle gives duke engineers complete control
10. Nanotech particles affect brain development in mice
11. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Franz Inc ., the leading supplier of Semantic Graph Database technology, today ... Bloor Research in its recent Graph Database Market Update report. ... it was rated as the easiest product to use.” – Bloor Research , ...
(Date:3/28/2017)... and WASHINGTON , March 28, 2017 ... GENEWIZ, will launch single-cell sequencing during the American Association for ... Washington Convention Center in Washington, D.C. ... perform differential gene expression of thousands of cells at ... Experts on-hand at AACR to ...
(Date:3/28/2017)... , March 28, 2017 Biostage, Inc. ... company developing bioengineered organ implants to treat cancers and ... today announced that Jim McGorry, CEO of ... BioEngineering panel at the MassBio 2017 Annual ... PM ET in Cambrige, Massachussetts. The 3D Printing ...
(Date:3/28/2017)... /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ... and clinical data from its phase 1/2 tendon repair study ... fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The clinical ... at 6 months and showed no serious adverse events related ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):